Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Genetically targeted adenovirus vector directed to CD40-expressing cells.

Natalya Belousova1, Nikolay Korokhov, Valentina Krendelshchikova

  • 1Division of Human Gene Therapy, Department of Medicine, University of Alabama at Birmingham, USA.

Journal of Virology
|October 15, 2003
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intranasal boosting induces variant-specific responses in SARS-CoV-2 vaccine-imprinted mice.

Nature communications·2026
Same author

AAV vectors for cancer gene therapy.

Advances in cancer research·2026
Same author

Neural stem cell delivery of oncolytic CRAd-S-pk7 immunotherapy for stage 3 ovarian cancer: Dose-regimen studies.

Molecular therapy. Oncology·2026
Same author

Long-acting interleukin-7 improves the efficacy of oncolytic viral therapy in glioblastoma.

Nature communications·2026
Same author

An intranasal adenoviral-vectored vaccine protects against highly pathogenic avian influenza H5N1 in naive and antigen-experienced animals.

Cell reports. Medicine·2026
Same author

Evaluation of high-throughput sequencing for replacing the conventional adventitious virus detection assays used for biologics.

NPJ vaccines·2025

This study engineered an adenovirus (Ad) vector to target CD40-expressing diseased cells. This novel gene therapy approach enhances specificity for potential cancer treatments and genetic immunization.

Area of Science:

  • * Molecular Biology
  • * Virology
  • * Gene Therapy

Background:

  • * Gene therapy efficacy relies on precise transgene delivery via therapeutic vectors.
  • * Adenovirus (Ad) vectors are widely used but often lack specific targeting capabilities.
  • * Targeting strategies are crucial for directing therapeutic payloads to diseased tissues.

Purpose of the Study:

  • * To develop an adenovirus (Ad) vector with enhanced tropism for CD40-expressing cells.
  • * To engineer a novel chimeric protein for Ad capsid modification.
  • * To evaluate the potential of this modified Ad vector for targeted gene delivery.

Main Methods:

  • * Adenovirus (Ad) fiber replacement strategy utilizing a protein chimera.
  • * Incorporation of Ad serotype 5 fiber, phage T4 fibritin, and human CD40 ligand (CD40L) domains.

Related Experiment Videos

  • * Assessment of viral tropism and cell entry via CD40 interaction.

    • Main Results:

    • * A functional chimeric protein was successfully incorporated into the Ad capsid.
    • * The modified Ad vector utilized CD40 as a surrogate receptor for cell entry.
    • * Efficient infection of CD40-positive dendritic cells and tumor cells was demonstrated.

    Conclusions:

    • * The engineered Ad vector demonstrates specific targeting of CD40-expressing cells.
    • * This modified virus serves as a prototype for advanced gene therapy vectors.
    • * Potential applications include genetic immunization and targeted tumor destruction.